Table 1 Characteristics of subjects in groups by the cut-off of exposure durations of endogenous estrogen
From: Endogenous estrogen exposure and chronic kidney disease; a 15-year prospective cohort study
| Â | Duration of endogenous estrogen exposure | ||
|---|---|---|---|
Variables | Group 1 < 11 years | Group 2 ≥11 years | Total |
Subjects (no)* | 1429 (47.0) | 1614(53.0) | 3043(100) |
Age(years) ** | 39.2 ± 8.8 | 46.6 ± 9.8 | 43.1 ± 10.1 |
Menarcheal age(years) ** | 13.7 ± 1.4 | 13.5 ± 1.5 | 13.6 ± 1.5 |
Body mass index (kg/m2) ** | 28.1 ± 4.6 | 28.5 ± 4.8 | 28.3 ± 4.7 |
Hypertension (yes)* | 195(13.8) | 425(26.8) | 620(20.6) |
Antihypertensive drug use * | 60(4.2) | 150(9.3) | 210(6.9) |
Angiotensin-converting-enzyme inhibitor use* | 9 (0.6) | 19(1.2) | 28(0.9) |
Diabetes type 2* | 110(7.9) | 238(15.1) | 348(11.7) |
Anti-diabetes type 2 drug use* | 39(2.7) | 92(5.7) | 131(4.3) |
Ever Smoker (yes) * | 82(5.8) | 72(4.5) | 154(5.1) |
eGFR (ml/min per1.73 m2) | 71.9 ± 8.5 | 70.7 ± 8.0 | 71.3 ± 8.3 |
Creatinine (mg/dl)** | 0.94 ± 0.08 | 0.92 ± 0.08 | 0.93 ± 0.06 |
Physical activity(MET- min/week)** | 1639 ± 2350.5 | 1577.7 ± 2049.4 | 1606.7 ± 2195.2 |
Menopause status (yes)* | 345(24.1) | 1420(88.0) | 1765(58) |
Menopausal age(years) ** | 44.1 ± 6.6 | 50.0 ± 4.0 | 48.8 ± 5.2 |
Total duration of pregnancies (years)** | 2.72 ± 1.4 | 3.09 ± 1.5 | 2.90 ± 1.5 |
Total duration of hormonal contraceptive use (years) ** | 0.55 ± 1.0 | 0.47 ± 0.5 | 0.53 ± 0.9 |
Total duration of breastfeeding (weeks) ** | 4.35 ± 2.6 | 2.25 ± 1.6 | 3.7 ± 2.5 |
Follow-up time (years)*** | 15.5(12.2,16.5) | 15.6(12.5,16.6) | 15.6(12.4,16.6) |